Company intelligence / Profile preview

Sonoran Biosciences

Scottsdale, Arizona, United Statessonoranbiosciences.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Sonoran Biosciences develops extended-release drug formulations for localized delivery at surgical sites. Their SB Gel platform enables multi-day release of drugs such as local anesthetics and antibiotics. Lead products include SBG004 for postoperative pain and SBG003 for prevention/treatment of SSIs. The company has reported positive preclinical results and received NIH funding but does not have active registered clinical trials yet.

Therapeutic areas: NeurologyInfectious Diseases
Modalities: sustained-release formulations (drug delivery)local anesthetics (e.g., bupivacaine)antibiotics (e.g., tobramycin, vancomycin)
Industry: Biotech

Drug pipeline

3 assets

SBG003

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Sonoran Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sonoran Biosciences.

Explore the full profile